TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a 3 comprehensive overview of targeted approaches - PubMed
a day ago
- #acute myeloid leukemia
- #myelodysplastic syndromes
- #TP53 mutation
- TP53-mutated AML and MDS are distinct myeloid malignancies with poor prognosis and high relapse rates.
- TP53 mutations, especially biallelic, are linked to complex karyotypes and chemoresistance.
- Current treatments like hypomethylating agents and venetoclax offer limited benefits with rare durable remissions.
- Novel therapies targeting mutant p53, restoring wild-type function, or synthetic lethality are being explored.
- The review covers TP53 biology, prognosis, and therapeutic strategies for TP53-mutated AML/MDS.
- Precision-guided, multimodal approaches are needed to improve outcomes in this high-risk group.